Drug Trial Radar · NCT00443053
Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
Last checked: Nov 20, 2026Latest source record: Mar 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,002
Actual
Start
Mar 2007
Primary completion
Jul 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Mar 5, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate fondaparinux 2.5mg subcutaneously once daily for 45 days in the treatment of acute (recent) superficial thrombophlebitis.
Conditions
- Thrombosis, Venous
Interventions
Fondaparinux 2.5mg or placeboDrug
Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With at Least on Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 47Time frame: Baseline to Day 47
Locations
227 sites in 17 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Brno, Czechia
GSK Investigational Site
Olomouc, Czechia
GSK Investigational Site
Pilsen, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Říčany, Czechia
GSK Investigational Site
Tábor, Czechia
GSK Investigational Site
Saku, Estonia
GSK Investigational Site
Tallinn, Estonia
GSK Investigational Site
Tallinn, Estonia
GSK Investigational Site
Tartu, Estonia
GSK Investigational Site
Abbeville, France
GSK Investigational Site
Alès, France
GSK Investigational Site
Amiens, France
GSK Investigational Site
Annecy, France
GSK Investigational Site
Annonay, France
GSK Investigational Site
Arras, France
GSK Investigational Site
Bordeaux, France
GSK Investigational Site
Brest, France
GSK Investigational Site
Clermont-Ferrand, France
GSK Investigational Site
Grenoble, France
GSK Investigational Site
Montpellier, France
GSK Investigational Site
Nice, France
GSK Investigational Site
Nîmes, France
GSK Investigational Site
Saint-Aubin-sur-Scie, France
GSK Investigational Site
Saint-Priest-en-Jarez, France
GSK Investigational Site
Tarbes, France
GSK Investigational Site
Toulon, France
GSK Investigational Site
Toulouse, France
GSK Investigational Site
Valenciennes, France
GSK Investigational Site
Villeurbanne, France
GSK Investigational Site
Baesweiler, Baden-Wurttemberg, Germany
GSK Investigational Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
GSK Investigational Site
Heidelberg, Baden-Wurttemberg, Germany
GSK Investigational Site
Karlsbad, Baden-Wurttemberg, Germany
Showing 40 of 227 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.